Continuous Glucose Monitoring Market

CGM Market Size & Growth (2019-2025)

The size of the Global Continuous Glucose Monitoring Market was worth USD 486 Million in 2018 and forecasted to grow at a CAGR of 16.1% from 2019 to 2025.

The continuous glucose monitoring is an advance medical technology for people with diabetes to check over their glucose levels for a particular period.

The continuous glucose monitoring market has grown widely across the world. Millions of people who are diabetic patients use these CGM to check the correct readings of blood glucose levels. The CGM devices also help diabetic patients to decrease the insulin dosage. The interpretations of these CGM devices will transmit to the receivers through a wireless network. They keep track of the readings over some time and that help in identifying minute changes that occur in the BGM by preventing hypoglycaemic conditions. 

Higher-order inside the industry for glucose monitoring has been building on advancements in the production and manufacturing monitoring medical devices and products. This glucose level in the blood is an essential parameter for the diagnosis and treatment of several diseases and infections. Due to the knowledge, healing practitioners and doctors mostly purchase and manage glucose monitoring devices to track the health of patients. Glucose monitoring leads to the production of tools and equipment that assist in real-time monitoring and sensing of glucose levels in this family. The head of the pieces to do minimally invasive medical media has also provided an incentive to the majority of the global continuous glucose monitoring market in recent times.

The increasing incidence of diabetes is a critical factor that could revolutionize the growth dynamics of the worldwide Continuous Glucose Monitoring Market. People whose plasma glucose levels undergo regular changes generally use glucose monitoring devices, which further increases market demand. In the present scenario, the majority of the diabetic population are using insulin pumps alongside CGM devices in their diabetic treatment procedure and this is further expected to accelerate the growth of the market. As per the International Diabetes Federation, in 2019, the population affected with diabetes were 463 million, in which, 4.2 million people dead. This figure is estimated to reach 530 million by 2030 and 700 million by 2045. 

Some specific products of this domain are growing at a good pace in the global market for continuous glucose monitoring. Moreover, protector real-time CGM systems have been bringing a tremendous demand as toward other glucose monitoring systems over the past decade. The need for continuous glucose monitoring market has been the biggest amongst people living with diabetes. This factor is forecasted to become more apparent over the coming years as the prevalence of diabetes increases across the globe.

REPORT COVERAGE:

This research report on the Global Continuous Glucose Monitoring (CGM) Market has been segmented and sub-segmented based on component type, end-user and region.

Continuous Glucose Monitoring (CGM) Market – By Component Type:

• Transmitters & Receivers
• Sensors
• Insulin Pumps

Based on the component type, the sensors segment is likely to account the most substantial share market value. These sensors use glucose oxidase to examine blood sugar levels. It is due to the conversion of glucose into hydrogen peroxide by glucose oxidase. Increasing geriatric population to fuel the demand for this segment. 

Continuous Glucose Monitoring (CGM) Market – By End User:

• Hospitals
• Homecare Diagnostics
• Others

Based on the end-user, the Homecare diagnostics hold for the highest share value. These homecare devices provide patients with less consumption of insulin dosage and help in monitoring the glucose levels accurately. This homecare device is likely to grow the market value due to its maximum productivity. 

Continuous Glucose Monitoring (CGM) Market – By Region:

• North America (the United States, Canada, Mexico and Rest of North America)
• Europe (United Kingdom, France, Spain, Germany, Italy and Rest of Europe)
• APAC (India, China, Japan, South Korea, Australia, New Zealand and Rest of APAC)
• Latin America (Brazil, Argentina, Chile and Rest of Latin America)
• The Middle East and Africa (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA)

Regionally, the North American CGM market is dominating the global CGM market. With over 90% of the share, the United States ruling the market in North America. This healthcare organization in Canada and the US has undoubtedly outdone the healthcare divisions of all other regions across the globe. The usage of continuous glucose monitoring practices in these nations has also become a leap in recent times. Furthermore, the sluggish and improper lifestyles of the characters in North America have presented rise to several diseases or disorders such as diabetes and high blood pressure. Owing to the circumstances mentioned above, this market inside the search for connected glucose monitoring in North America has been rising at an astronomical rate in recent times.

Followed by North America, this industry for compatible glucose monitoring in Europe has additionally developed at a healthy pace over the preceding several years. It owes to the presence of a knowledgeable medical practitioner that can suggest the right products for continuous glucose monitoring to the masses.

Key market participants leading the Global Continuous Glucose Monitoring Market profiled in this report are:

• Dexcom Inc.
• Roche Diagnostics
• Medtronic plc.
• Novo Nordisk
• Abbott Laboratories
• Animas Corporation
• Ypsomed AG.
• Bayer AG
• Insulet Corporation
• Sensonic Corporation

Recent Market Developments

On February 21, 2020, Dexcom has announced that it has gained CE mark for its G6 continuous glucose monitoring where it can be used safely over pregnant women. Dexcom is behind the pregnancy patients as it looks after the patients with Type 1 and Type 2. The company is expanding its patient pregnancy population for its signature device.

On September 17, 2019, Medtronic introduced a new system called Envision Pro, for the continuous monitoring system. It can be thrown away after use, and zero calibration CGM system. This technology is to give accurate results while checking type I and type ll diabetes patients. 

On October 01, 2018, Novo Nordisk made a public statement that it is going to launch connected insulin pens for patients who have diabetes. These insulin pens will be able to share information or ideas with CGM and (BGM) blood glucose monitoring systems. It is a very long awaiting program as researchers are trying to launch smart insulin pens.